MRI Findings and Prediction of Time to Progression of Patients with Hepatocellular Carcinoma Treated with Drug-eluting Bead Transcatheter Arterial Chemoembolization

Seungho Lee,1 Kyung Ah Kim,2 Mi-Suk Park,1 and Sun Young Choi3

1Department of Radiology, Research Institute of Radiological Science, Yonsei University, College of Medicine, Seoul; 2Department of Radiology, St. Vincent’s Hospital, College of Medicine, The Catholic University of Korea, Seoul; 3Department of Radiology and Medical Research Institute, School of Medicine, Ewha Womans University, Seoul, Korea

Received: 16 January 2015
Accepted: 1 April 2015

Address for Correspondence:
Kyung Ah Kim, MD
Department of Radiology, St. Vincent’s Hospital, the Catholic University of Korea, 93 Jungbu-daero, Paldal-gu, Suwon 442-723, Korea
Tel: +82.31-249-8496, Fax: +82.31-247-5713
E-mail: bellenina@daum.net

INTRODUCTION

Hepatocellular carcinoma (HCC) is the most common primary liver cancer and one of the common causes of cancer death (1). HCC can be cured through liver resection and liver transplantation, but many patients are not eligible for surgery when diagnosed. Transcatheter arterial chemoembolization (TACE) is a commonly used locoregional therapy for unresectable HCC in patients with preserved liver function. TACE is recommended for intermediate-stage HCC with multinodular disease and no vascular invasion or extrahepatic metastasis (2), but post-surgical survival benefits remain controversial (3-6). Nevertheless, evidence suggests that chemoembolization improves survival in patients with unresectable HCC (7, 8). TACE with drug-eluting beads (DEB) was introduced, in which loaded drugs are delivered to target lesions by a transcatheter approach, and the beads elute drugs at controlled and sustained doses for a prolonged time. This approach allows higher and prolonged intra-tumoral drug retention and low release of drug into systemic circulation (9-11). Previous study by Song et al. (12) reported that DEB-TACE showed better treatment response and delayed tumor progression compared with conventional lipiodol-based TACE (cTACE). DEB-TACE is associated with decreased liver toxicity and fewer drug-related adverse events such as post-embolization syndrome or alopecia, allowing the use of higher doses of chemotherapeutic agents. Consequently, DEB-TACE offers higher rates of complete response, objective response, and disease control compared to cTACE (12-15).

Multi-detector computed tomography (MDCT) and magnetic resonance imaging (MRI) are usually used to evaluate treatment response after cTACE or DEB-TACE. Imaging findings on computed tomography (CT) after DEB-TACE have been described for HCC (16), but MRI findings after DEB-TACE and the relationship between MRI findings and time to progression have not been assessed fully. We evaluated MRI after DEB-TACE to see if there was a relationship between MRI findings and time to progression.

MATERIALS AND METHODS

Subjects

Between December 2009 and May 2012, 216 patients diagnosed
with HCC according to the American Association for the Study of Liver Diseases practice guidelines were treated with DEB-TACE. Among them, patients were enrolled if they had liver MRI within 3 months after DEB-TACE. In total, 48 patients were included in the study.

**DEB-TACE treatment protocol**

Doxorubicin and DEB (DC Bead®, Biocompatibles, Surrey, UK) amounts were chosen based on the extent of tumor burden. In this study, 2 or 4 mL of DEB with bead diameters ranging from 100 to 300 μm or 300 to 500 μm were loaded with doxorubicin according to manufacturer’s guidelines. The endpoint for embolization was stasis of blood flow in the arterial feeders to the tumor.

**First follow-up MRI protocol**

MRI examination was performed using two 3.0-T MR systems [(n = 42, Magnetom Tim Trio, Siemens Healthcare, Erlangen, Germany; n = 6, Achieva, Philips Medical Systems, Best, Netherlands)]. The imaging protocol for the Magnetom Tim Trio system included T1-weighted in-phase and out-of-phase images (TR, 150 ms; TE (in-phase/out-of-phase), 2.46 ms/1.23 ms; slice thickness, 6 mm; flip angle, 65°; ETL, 1; matrix, 256×192; FOV, 370 mm; band width, 1,628 Hz/Px), a breath-hold T2-weighted spin echo sequence (T2WI) (TR, 1,600 ms; TE, 81 ms; slice thickness, 4 mm; flip angle, 140°; ETL, 1; matrix, 256×192; FOV, 370 mm; band width, 260 Hz/Px), and diffusion-weighted images (DWI) with b values of 50, 400, and 800 sec/mm² (TR, 5,400 ms; TE, 69 ms; slice thickness, 5 mm; flip angle, 90°; ETL, 1; matrix, 192×108; FOV, 370 mm; band width, 1,736 Hz/Px). Precontrast images were acquired with three-dimensional T1-weighted fat-suppressed gradient-echo images (T1WI) (TR, 2.54 ms; TE, 0.95 ms; slice thickness, 2 mm; flip angle, 13°; ETL, 1; matrix, 256×192; FOV, 370 mm; band width, 814 Hz/Px).

The imaging protocol for the Achieva MR system was similar: 3 Echo T1-weighted fast field-echo (TR, 218.97 ms; TE, 2.30 ms; slice thickness, 5 mm; flip angle, 20°; ETL, 3; matrix, 160×199; FOV, 370 mm; band width, 2,701 Hz/Px), a breath-hold fat-suppressed T2WI (TR, 1,000 ms; TE, 80 ms; slice thickness, 5 mm; flip angle, 90°; ETL, 75; matrix, 272×270; FOV, 370 mm; band width, 530 Hz/Px), DWI with b values of 50, 400, and 800 sec/mm² (TR, 1,612.8 ms; TE, 57.44 ms; slice thickness, 5 mm; flip angle, 90°; ETL, 29; matrix, 112×108; FOV, 360 mm; band width, 2,157 Hz/Px), and precontrast images with three-dimensional T1-weighted fat-suppressed ultra-fast gradient-echo images (TR, 3.04 ms; TE, 1.44 ms; slice thickness, 4 mm; flip angle, 10°; ETL, 46; matrix, 256×258; FOV, 370 mm; band width, 723 Hz/Px). The apparent diffusion coefficient (ADC) map from the DWI with three b values acquired from each magnet was made automatically using commercially available software with a mono-exponential model.

Contrast agent was injected intravenously through a 20-gauge intravenous catheter placed into a peripheral vein, followed by a 20-mL saline flush at a rate of 2 mL/sec. Gadodiamide (n = 30; Omniscan; GE Healthcare, Oslo, Norway; 0.1 mM/kg) was used as the contrast material. After contrast injection, dynamic images were obtained in four phases (arterial, portal, hepatic, and equilibrium) using the same sequence used for precontrast images with 18-20 sec for acquisition time and 30 sec time intervals for each scan. The delay time for arterial phase imaging was determined using the MR fluoroscopic test bolus detection technique. Subtraction images were acquired through post-imaging processing that subtracted the precontrast image from the arterial phase image.

**Last follow-up CT protocol**

The last follow-up CT was defined as the last CT examination obtained before death or the first CT examination to find progressive disease in this study. For follow-up CT examination, images were obtained with a 16-MDCT (Somatom Sensation 16, Siemens Healthcare, Erlangen, Germany) and a 64-MDCT scanner (Somatom Sensation 64, Siemens Healthcare, Erlangen, Germany and LightSpeed VCT, GE Health care, Milwauke, Wis). An unenhanced scan was obtained before administration of contrast media. All patients received a 2 mL/kg dose (total volume, < 150 mL) of nonionic contrast material (iopromide; Ultrastiv 300, Bayer Schering Pharma, Wayne, NJ). A late arterial phase scan was obtained with a delay of 18 sec after attenuation of the abdominal aorta reached 100 HU. Portal venous and delayed phase imaging were obtained with a delay of 30 and 150 sec, respectively, after the end of the previous phase. Scanning parameters were as follows: 0.5-sec rotation time; 100-120 kV; 200-250 mAs; 0.6-mm beam collimation; beam pitch, 1; and 3-mm slice thickness.

**Image analysis on first follow-up MRI and treatment response**

Follow-up images were reviewed in consensus by two radiologists with 6 and 5 yr of experience in abdominal imaging who did not perform the DEB-TACE and who were blinded to all clinical information except that all patients had undergone DEB-TACE. MRI images were reviewed in two sessions. Each image set (T2WI, precontrast T1WI, dynamic images involving arterial, portal, hepatic, and equilibrium phases, subtraction image, HBP and DWI images) was evaluated and the following documented: (a) the pattern of arterial enhancement of treated tumor [no enhancement, peripheral rim enhancement, peripheral nodular enhancement and solid enhancement (with enhancement in whole or mainly tumor)]; (b) the presence of washout on late dynamic images involving portal, hepatic, and equilibrium phases; (c) the presence of an arterioportal (AP) shunt; (d) tumor signal intensity on T2WI using a three-grade scale:
hyperintense, isointense, and hypointense compared with signal integrity of adjacent liver parenchyma; (e) the presence of intratumoral septa in the cystic or necrotic portion of the tumor (no septa, fine septa < 2 mm, or thick septa ≥ 2 mm); (f) ADC value of each tumor; (g) the presence of enhancing tissue on the subtraction image; and (h) treatment response according to the modified Response Evaluation Criteria in Solid Tumors (mRECIST). Treatment response of the target lesion according to mRECIST was evaluated as follows: complete response (CR), disappearance of any intratumoral arterial enhancement; partial response (PR), at least a 30% decrease in the sum of diameters of the viable (enhancement in the arterial phase) target lesion, taking as reference the baseline sum of the diameters of the target lesion; stable disease (SD), any cases not meeting the definition for partial response; and progressive disease (PD), an increase of at least 20% in the sum of the diameters of the viable (enhancing) target lesion, taking as reference the smallest sum of the diameters of the viable (enhancing) target lesion recorded since the start of treatment. Tumor treatment response was evaluated on the last follow-up CT according to mRECIST. Recurrence of the treated tumor after DEB-TACE was defined as arterial enhancement that was newly developed in the non-enhancing portion of the treated tumor. Tumor recurrence was regarded as progressive disease.

Statistical analysis
The relationship between imaging findings on first follow-up MRI and detection of viable tumor on last follow-up CT was assessed using Pearson’s chi-squared test or Fisher’s exact test. A P value less than 0.05 was considered to indicate a statistically significant difference. A cut-off ADC value was calculated to differentiate treated lesions with or without viable tumor by ROC curve and the diagnostic performance of the ADC value to predict the presence of viable tumor tissue using this threshold was assessed. For the calculation of TTP, disease progression as defined by mRECIST was used as an end point. The time to progression was defined as the time between DEB-TACE data and the date of the imaging study that identified disease progression among the follow-up imaging studies. Cox regression univariate analysis was used to identify independent factors to predict TTP among age, gender, American Joint Committee on Cancer (AJCC) staging classification, Barcelona Clinic Liver Cancer (BCLC) staging classification, and MRI findings. Hazard ratio and 95% confidence intervals were calculated for each factor. Each factor that was statistically significant on univariate analysis was tested in multivariate models. TTP for significant factor on multivariate model was calculated using the Kaplan-Meier method and compared using the log-rank test. Statistical analyses were performed using SAS software version 9.2 (SAS, Cary, NC, USA).

Ethics statement
The study protocol was approved by the institutional review board of Severance Hospital (IRB No. 4-2014-0203). Informed consent was waived by the board.

RESULTS
Patient characteristics are summarized in Table 1. In total, the study included 36 men and 12 women with a mean age of 58 yr (age range, 35-77 yr) and 60 tumor nodules: 40 had one tumor lesion; 5 had two lesions; 2 had three lesions; and one had four lesions (36 nodules ≥ 3 cm and 24 nodules < 3 cm; mean size, 3.2 cm; range 1.0-14.5 cm). DEBs were 100-300 μm in 24 lesions, 300-500 μm in 31 lesions, and both 100-300 μm and 300-500 μm in 5 lesions. All patients had liver cirrhosis. The Child-Pugh class for liver function was class A in 43 patients (89.6%) and class B in 5 patients (8.3%). The most common etiology of liver cirrhosis was viral hepatitis B (36 patients, 75%). The AJCC stages were stage I in 13 (27.1%), stage II in 26 (54.2%), stage III in 6 (12.5%), and stage IV in 3 (6.2%) patients. The BCLC stages were stage 0 in 11 (22.9%), stage A in 17 (35.4%), stage B in 13 (27.1%), and stage C in 7 patients (14.6%). The mean interval between DEB-TACE treatment and follow-up MRI examination was 33.2 days (range, 21-61 days). The mean interval from the first DEB-TACE to the last follow-up CT was 16.1 months (range, 1-33.3 months). Twelve of the patients died during the follow-up period. The causes of death were multi-organ failure in 1 patient and disease progression in 11 patients. Based on the first fol-
low-up MRI for each patient (n = 48), CR was achieved in 20 (41.7%), PR in 21 (43.8%), and SD in 7 (14.6%) patients. Table 2 shows a summary of the treatment responses per lesion according to mRECIST as evaluated on the first follow-up MRI and last follow-up CT. Based on the first follow-up MRI, CR was achieved in 30 (50.0%) lesions. Residual tumors were detected in 30 lesions (50.0%), with PR in 22 (36.7%) and SD in 8 (13.3%) lesions. There was no case of progressive disease. In the assessment of treatment response for each lesion at last follow-up CT (n = 60), CR was achieved in 16 (26.7%), PR in 6 (10%), SD in 2 (3.3%) and PD in 36 lesions (60.0%) (Table 2).

Table 2. Treatment response per lesion on first MRI after DEB-TACE and last CT according to mRECIST

| Treatment response | First follow-up MRI | Last follow-up CT |
|--------------------|---------------------|------------------|
| Complete response  | 30                  | 16               |
| Partial response   | 22                  | 6                |
| Stable disease     | 8                   | 2                |
| Progressive disease| 0                   | 36               |

mRECIST, modified Response Evaluation Criteria in Solid Tumors; DEB, drug-eluting bead; TACE, transarterial chemoembolization; HCC, hepatocellular carcinoma.

Table 3. Imaging findings on first MRI after DEB-TACE and viable tumor per-lesion evaluated on last CT

| Images                                | No viable tumor | Viable tumor | P value |
|---------------------------------------|-----------------|--------------|---------|
| Arterial enhancement                  |                 |              |         |
| None/rim shape                        | 4/11            | 3/12         | < 0.001*|
| Peripheral nodular/solid              | 1/0             | 20/9         |         |
| Washout                               |                 |              |         |
| Yes                                   | 0               | 24           | < 0.001*|
| No                                    | 16              | 20           |         |
| AP shunt                              |                 |              | 0.437   |
| Yes                                   | 9               | 24           |         |
| No                                    | 7               | 20           |         |
| Signal intensity on T2                 |                 |              |         |
| Hyper                                 | 2               | 5            | 0.999   |
| Iso/Hypo                              | 13/1            | 35/4         |         |
| Intratumoral septa                    |                 |              | 0.486   |
| None                                  | 14              | 34           |         |
| < 2 mm/ ≥ 2 mm                        | 2/0             | 3/7          |         |
| Enhancing tissue on subtraction image |                 |              | < 0.001*|
| Yes                                   | 0               | 34           |         |
| No                                    | 16              | 10           |         |
| Total                                 | 16              | 44           |         |

* P value is statistically significant. DEB, drug-eluting bead; TACE, transarterial chemoembolization; HCC, hepatocellular carcinoma; AP, arteriportal; T2WI, T2-weighted image.

Fig. 1. A 61-yr-old man treated with DEB-TACE for HCC. (A) An arterial enhancing mass (white arrowhead) is noted on the MRI obtained before DEB-TACE. (B, C) The treated lesion shows peripheral rim enhancement on arterial phase (white arrow) (B), and equilibrium phase (C) of axial fat-suppressed T1-weighted 3D GRE images in the follow-up MRI acquired 36 days after DEB-TACE. (D) Rim enhancement (white arrow) is identified as being more prominent on the subtraction image between the precontrast image and the arterial phase image. (E) The treated lesion shows high-signal intensity on T2-weighted image. Tumor response was determined as complete response on the first follow-up MRI.
Imaging findings on first follow-up MRI and viable tumor on last follow-up CT

Based on MRI image analysis of arterial enhancement patterns, seven target lesions were not enhanced on arterial phase and 23 lesions showed rim enhancement on arterial phase (Fig. 1) (Table 3). Peripheral nodular enhancement was depicted in 21 lesions (Fig. 2) and solid enhancement was observed in 9 lesions. The last follow-up CT detected viable tumor tissue in three of 7 lesions with no arterial enhancement (42.9%) and 12 of 23 lesions with rim enhancement (52.2%). Viable tumor was identified in 20 of 21 lesions with peripheral nodular enhancement (95.2%), and in all 9 target lesions with solid enhancement (100%). In other words, 29 among thirty target lesions with peripheral nodular or solid enhancement pattern on arterial phase of first follow-up MRI also showed viable tumor tissue on the last follow-up CT. The presence of viable tumor was statistically different according to arterial enhancement pattern (no or rim shape enhancement vs. peripheral nodular or solid enhancement) (P < 0.001). Washout on portal or equilibrium phases was found in 24 out of 60 target lesions, and viable tumor was detected on CT in all 24 lesions that showed washout on the late dynamic phase (100%) compared to 20 (55.6%) of the 36 lesions without washout (P < 0.001). All 34 lesions with enhancing tissue on subtraction images showed viable tumor tissue on the last follow-up CT (100%) (Fig. 3), compared to 10 (38.5%) of the 26 lesions with no enhancing tissue on subtraction images (P < 0.001). An AP shunt was found in 33 lesions. On T2WI, 7 lesions had high-signal, 48 had iso-signal, and 5 had low-signal intensity. Intratumoral septa were detected in 12 lesions (20%), 5 with thin and 7 with relatively thick septa. All 7 lesions with relatively thick septa and 3 of the 5 lesions with thin septa showed residual viable tumor. There was no difference in the presence of viable tumor according to the presence of an AP shunt, signal intensity on T2WI, or intratumoral septa. The mean ADC value on the first follow-up MRI of target lesions with viable tumor tissue on the last follow-up CT (n = 44) was 1.607 × 10⁻³ mm²/sec, which was higher than that of lesions without viable tumor tissue (1.576 × 10⁻³ mm²/sec) (n = 16). The cut-off value

http://dx.doi.org/10.3346/jkms.2015.30.7.965
http://jkms.org
calculated by ROC curve to differentiate treated lesions with or without tumor progression was $1.779 \times 10^{-3} \text{ mm}^2/\text{sec}$ and the diagnostic performance of the ADC value to predict tumor progression using this threshold showed a sensitivity of 79.6%, specificity of 50%, and AUC of 0.583.

### Table 4. Univariate Cox-regression analysis of TTP after DEB-TACE according to imaging findings on the first MRI

| Factors                      | Time to progression | Log-rank P value |
|------------------------------|---------------------|------------------|
| Gender                       | 0.770 0.347-1.708   | 0.520            |
| Age                          | 1.012 0.973-1.053   | 0.539            |
| AJCC                         | 0.967 0.436-2.141   | 0.933            |
| BCLC                         | 1.204 0.612-2.37    | 0.591            |
| Tumor size                   | 1.044 0.936-1.164   | 0.441            |
| Arterial enhancement         | 2.693 1.352-5.362   | 0.004*           |
| Washout                      | 3.168 1.58-6.351    | 0.004*           |
| AP shunt                     | 0.983 0.505-1.913   | 0.959            |
| Intratumoral septa           | 1.672 0.776-3.602   | 0.190            |
| Signal intensity on T2WI     | 0.774 0.189-3.159   | 0.308            |
| Enhancing tissue on subtraction image | 3.789 1.789-8.023 | 0.001*           |

*P value is statistically significant. TTP, time to progression; DEB, drug-eluting bead; TACE, transarterial chemoembolization; CI, confidence interval; HR, hazard ratio.

### Table 5. Multivariate Cox-regression analysis of TTP after DEB-TACE according to imaging findings on the first MRI

| Factors                      | Time to progression | Log-rank P value |
|------------------------------|---------------------|------------------|
| Arterial enhancement         | 0.559 0.145-2.145   | 0.396            |
| Washout                      | 2.046 0.668-6.264   | 0.210            |
| Enhancing tissue on subtraction image | 3.953 1.271-12.291 | 0.018*           |

*P value is statistically significant. TTP, time to progression; DEB, drug-eluting bead; TACE, transarterial chemoembolization; CI, confidence interval; HR, hazard ratio.

### Time to progression

Univariate analysis using the Cox-regression test revealed that arterial enhancement (HR = 2.693, P = 0.004), presence of washout (HR = 3.168, P = 0.001) and enhancing tissue on subtraction images (HR = 3.789, P = 0.001) were significant predictors of TTP (Table 4). Gender, age, tumor stages and other MRI findings such as the presence of an AP shunt, the presence of intratumoral septa, and signal intensity on T2WI were not significant.

---

**Fig. 3.** A 67-yr-old woman treated with DEB-TACE for HCC. (A) HCC is noted on the arterial phase image of the liver MRI acquired prior to treatment. (B) After DEB-TACE, an enhancing portion within the treated tumor is not detected on the arterial phase. (C) Meanwhile, subtle washout is suspected on the equilibrium phase of a follow-up MRI taken 30 days after DEB-TACE. (D) A small arterial enhancing portion is noted on the subtraction image. (E) Detecting residual tumor on axial T2-weighted image is difficult.
predictors of TTP. Based on the subsequent multivariate analysis, however, only enhancing tissue on subtraction images (HR = 3.953, \( P = 0.018 \)) was a significant predictor for shorter TTP (Table 5). TTP was statistically longer without enhancing tissue on the subtraction image (601 days without vs. 287 days with, \( P < 0.001 \)).

**DISCUSSION**

MDCT and MRI are useful imaging modalities for evaluating treatment response and predicting prognosis after TACE (17-22). In particular, evaluation of prognosis in diverse aspects have been investigated among diverse aspects beyond size criteria. Recently, radiologic CR achieved after first TACE on CT, EASL and mRECIST responses, and ADC change relative to baseline on MRI have been reported as independent predictors for prognosis after TACE (17, 20, 21). Our study showed that imaging findings detected on the first follow-up MRI obtained after DEB-TACE for HCC can be used to predict TTP and the presence of viable tumor tissue on follow-up CT. Arterial enhancement, late washout, and enhancing tissue detected on subtraction images were significant imaging predictors for viable tumor on follow-up MRI and only enhancing tissue detected on subtraction images was significant imaging predictor for TTP. Our findings are in agreement with other reports on imaging of target lesions after cTACE that residual enhancement and washout of target lesions are related to tumor recurrence, time to progression, and overall survival (5, 23). Chung et al. (16) found that progression of treated HCC was different according to arterial enhancement pattern on CT after DEB-TACE. This study also found that the presence of residual and recurrent tumor tissue on the last CT examination differed according to arterial enhancement patterns on the first follow-up MRI. The likelihood that viable tumor tissue will be detected during follow-up increases when the target lesion shows a peripheral nodular or solid enhancement pattern on the arterial phase of the first follow-up MRI. These imaging findings show directly viable tumor. Therefore, if these findings are detected on first follow-up MRI, immediate additional treatment and close follow-up are strongly recommended. Tumor recurrence was rare in treated lesions showing rim enhancement on arterial phase. The arterial enhancement pattern of rim enhancement may be associated with hyperemia or fibrosis rather than viable tumor or high possibility of tumor recurrence. It was impossible to classify signal intensities of DWI into a single group due to marked heterogeneity of DWI signal intensity for most lesions in this study although DWI has been reported a significant prognostic predictor after TACE. The diagnostic performance of the ADC value for predicting tumor progression using calculated threshold was also not excellent.

In this study, MRI subtraction images were the most helpful for predicting the presence of viable tumor on follow-up CT and time to progression, more so than arterial phase images. The small arterial enhancing portion of an image, representing the residual viable tumor, can be accentuated on subtraction images, allowing the subtraction image to facilitate the detection of small viable tumors that are difficult to distinguish. Subtraction images can help identify residual viable tumor tissue in markedly heterogenous masses or adjacent liver parenchyma displaying various signal intensity changes after DEB-TACE involving necrosis, infarction, and hemorrhage, among others. When gadoxetic acid is used for MRI contrast, subtraction images may be helpful in detecting small residual tumors in some degraded images, due to the deleterious effect of gadoxetic acid on arterial phase image quality (24).

Follow-up study after TACE is usually performed by CT. Lipiodol accumulation within the tumor after cTACE with lipiodol can be seen as high attenuation on CT, which can make it difficult to evaluate lipiodol uptake on MRI due to variable signal intensities of the lipiodol (25). In contrast, particles used in DEB-TACE do not affect attenuation or cause signal changes. Accordingly, MRI offers better contrast for soft tissues and higher spatial resolution with sensitivity than CT for the evaluation of tumor response after DEB-TACE (25).

Residual tumors that are nodular in shape with a smooth margin at the inner surface of the treated tumor and nearly complete necrotic change (as shown in Fig. 2) are difficult to detect after cTACE with lipiodol, but are often detected after DEB-TACE, possibly due to the different characteristics of the embolic materials in DEB-TACE. Gelfoam is prepared manually and arterial obstruction is heterogeneous and lasts less than 72 hr (15). Accordingly, cTACE with lipiodol enables more chemoperfusion than a real chemoembolization because the material cannot occlude the arterial tumor vessels completely or permanently (6). In addition, rapid separation of doxorubicin and lipiodol, due to differences in hydrophilic properties, and coalescence inside the infusion catheter or the blood vessel increases the droplet size in cTACE with lipiodol, compared to the controlled and sustained drug elution with DEB-TACE (26). In this study, we sometimes observed that residual arterial enhancing portions within the treated tumor, corresponding to viable tumor tissue, decreased during the initial few months of first and second imaging follow-up after DEB-TACE without additional treatment. We attributed these changes to sustained drug elution after DEB-TACE. The smaller bead diameters of DEB-TACE also achieve a more distal embolization than in cTACE with lipiodol, further obstructing collateral channels and necessitating superselective embolization (27). When small beads are used, extensive liquefactive and coagulative necrosis radiates outwards from the centers of the DC bead clusters (27). A stronger anticaner effect in the area exposed to the drug with DEB-TACE could increase the extent of necrotic changes within the tumor, resulting in a clearer margin between the necrotic and viable
portions.

There were several limitations in this study. First, the study population was small. Second, we could not use histopathologic evaluation as the gold standard for the viable tumor portion. Instead, we considered local recurrence of target lesions on follow-up imaging to indicate the presence of residual viable tumor after DEB-TACE. There is the possibility of more false-negative cases due to an insufficient follow-up period. Third, the windows of follow-up imaging after treatment were relatively wide, each within 3 months. A fixed and more precise scan time after treatment would have made the study more homogenous and comparable.

In conclusion, enhancing tissue on subtraction images from MRI after DEB-TACE was predictive for longer TTP.

DISCLOSURE

The authors declare there is no conflict of interest.

AUTHOR CONTRIBUTION

Conceived and designed the experiments: Kim KA, Park MS. Performed the experiments: Park MS, Choi SY. Analyzed the data: Kim KA, Lee S. Wrote the paper: Kim KA, Lee S. Agree with manuscript results and conclusions: all authors.

ORCID

Seungsoo Lee http://orcid.org/0000-0002-6268-575X
Kyung Ah Kim http://orcid.org/0000-0002-8962-5433
Mi-Suk Park http://orcid.org/0000-0001-5817-2444
Sun Young Choi http://orcid.org/0000-0003-2488-1183

REFERENCES

1. Kim KA, Kim MJ, Choi JY, Chung YE. Development of hepatocellular carcinomas in patients with absence of tumors on a prior ultrasound examination. Eur J Radiol 2012; 81: 1450-4.
2. Lencioni R. Chemoembolization for hepatocellular carcinoma. Semin Oncol 2012; 39: 503-9.
3. Pelletier G, Roche A, Ink O, Anciaux ML, Derhy S, Rougier P, Lenoir C, Attali P, Etienne JP. A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. J Hepatol 1990; 11: 181-4.
4. Lin DY, Liaw YF. Hepatic arterial embolization in patients with unresectable hepatocellular carcinoma—a randomized controlled trial. Gastroenterology 1988; 94: 453-6.
5. Llovet JM, Real MI, Montaña X, Planas R, Coll S, Aponte J, Ayuso C, Sala M, Muchat J, Solà R, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002; 359: 1734-9.
6. Marelli L, Stigliano R, Triantos C, Senzolo M, Cholongitas E, Davies N, Tibballs J, Meyer T, Patch DW, Burroughs AK. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 2007; 30: 6-25.
7. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 2003; 37: 429-42.
8. Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, Fan ST, Wong J. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35: 1164-71.
9. Sottani C, Poggi G, Quaretti P, Regazzi M, Montagna B, Quaquarini E, Imbriani M, Leoni E, Di Cesare P, Riccardi A, et al. Serum pharmacokinetics in patients treated with transarterial chemoembolization (TACE) using two types of epirubicin-loaded microspheres. Anticancer Res 2012; 32: 1769-74.
10. Jordan O, Denys A, De Baere T, Boulens N, Doelker E. Comparative study of chemoembolization loadable beads: in vitro drug release and physical properties of DC bead and hepasphere loaded with doxorubicin and irinotecan. J Vasc Interv Radiol 2010; 21: 1084-90.
11. Lee KH, Liapi EA, Cornell C, Reb P, Buijs M, Vossen JA, Ventura VP, Geschwind JF. Doxorubicin-loaded QuadraSphere microspheres: plasma pharmacokinetics and intratumoral drug concentration in an animal model of liver cancer. Cardiovasc Intervent Radiol 2010; 33: 576-82.
12. Song MJ, Chun HJ, Song do S, Kim HY, Yoo SH, Park CH, Bae SH, Choi JY, Chang UI, Yang JM, et al. Comparative study between doxorubicin-eluting beads and conventional transarterial chemoembolization for treatment of hepatocellular carcinoma. J Hepatol 2012; 57: 1244-50.
13. Sacco R, Bargellini I, Bertini M, Bozzi E, Romano A, Petruzzi P, Tumino E, Ginanni B, Federici G, Cioni R, et al. Conventional versus doxorubicin-eluting bead transarterial chemoembolization for hepatocellular carcinoma. J Vasc Interv Radiol 2011; 22: 1545-52.
14. Lammer J, Malagari K, Vogl T, Pilleul F, Denys A, Watkinson A, Pitton M, Sergent G, Pfammatter T, Terraz S, et al.; PRECISION V Investigators. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 2010; 33: 41-52.
15. Burrel M, Reig M, Forner A, Barrufet M, de Lope CR, Tremosini S, Ayuso C, Attali P, Etienne JP. Radiologic-pathologic analysis of the gold standard for the viable tumor portion. Cardiovasc Intervent Radiol 2010; 33: 191-200.
16. Chung WS, Lee KH, Park MS, Lee YJ, Kwon J, Baek SE, Kim MJ. Enhancement patterns of hepatocellular carcinoma after transarterial chemoembolization using drug-eluting beads on arterial phase CT images: a pilot retrospective study. AJR Am J Roentgenol 2012; 199: 349-59.
17. Kim BK, Kim SU, Kim KA, Chung YE, Kim MJ, Park MS, Park JY, Kim DY, Ahn SH, Kim MD, et al. Complete response at first chemoembolization is still the most robust predictor for favorable outcome in hepatocellular carcinoma. J Hepatol 2015; 62: 1304-10.
18. Kamei IB, Bluemke DA. Magnetic resonance imaging of the liver: assessing response to treatment. Top Magn Reson Imaging 2002; 13: 191-200.
19. Chaparro J, Wood LD, Lin M, Duran R, Corinisi T, Lesage D, Charu V, Scherthaner B, Wang Z, Tacher V, et al. Radiologic-pathologic analysis of contrast-enhanced and diffusion-weighted MR imaging in patients with...
20. Vandecaveye V, Michielsen K, De Keyzer F, Laleman W, Komuta M, Op de beeck K, Roskams T, Nevens F, Verslype C, Maleux G. Chemoembolization for hepatocellular carcinoma: 1-month response determined with apparent diffusion coefficient is an independent predictor of outcome. Radiology 2014; 270: 747-57.

21. Gillmore R, Stuart S, Kirkwood A, Hameeduddin A, Woodward N, Burroughs AK, Meyer T. EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization. J Hepatol 2011; 55: 1309-16.

22. Kim BK, Kim KA, An C, Yoo EJ, Park JY, Kim do Y, Ahn SH, Han KH, Kim SU, Kim MJ. Prognostic role of magnetic resonance imaging vs. computed tomography for hepatocellular carcinoma undergoing chemoembolization. Liver Int 2015; 35: 1722-30.

23. Katyal S, Oliver JH, Peterson MS, Chang PI, Baron RL, Carr BL. Prognostic significance of arterial phase CT for prediction of response to transcatheter arterial chemoembolization in unresectable hepatocellular carcinoma: a retrospective analysis. AJR Am J Roentgenol 2000; 175: 1665-72.

24. Davenport MS, Viglianti BL, Al-Hawary MM, Caoli EM, Kaza RK, Liu PS, Maturen KE, Chenevert TL, Hussain HK. Comparison of acute transient dyspnea after intravenous administration of gadoxetate disodium and gadobenate dimeglumine: effect on arterial phase image quality. Radiology 2013; 266: 452-61.

25. Minami Y, Kudo M. Therapeutic response assessment of transcatheter arterial chemoembolization for hepatocellular carcinoma: ultrasonography, CT and MR imaging. Oncology 2013; 84: 58-63.

26. Ippolito D, Fior D, Bonaffini PA, Capraro C, Leni D, Corso R, Sironi S. Quantitative evaluation of CT-perfusion map as indicator of tumor response to transarterial chemoembolization and radiofrequency ablation in HCC patients. Eur J Radiol 2014; 83: 1665-71.

27. Malagari K. Drug-eluting particles in the treatment of HCC: chemoembolization with doxorubicin-loaded DC Bead. Expert Rev Anticancer Ther 2008; 8: 1643-50.